TY - JOUR
T1 - FLT3 tyrosine kinase inhibition as a paradigm for targeted drug development in acute myeloid leukemia
AU - Grunwald, Michael R.
AU - Levis, Mark J.
PY - 2015/7/1
Y1 - 2015/7/1
N2 - Therapy targeting specific somatic mutations has become an increasingly important part of cancer therapy over the past 20 years. In particular, tyrosine kinase inhibitors (TKIs) have become a critical component of treatment for both solid tumors and hematologic malignancies. Since mutations in the FMS-like tyrosine kinase 3 (FLT3) gene are relatively common in acute myeloid leukemia (AML), activating mutations in FLT3 represent an appealing target for drug development. Efforts are well underway to develop FLT3 inhibitors and to incorporate these agents into AML therapy. As the genetic landscape of AML has been mapped, other attractive targets for therapy have been discovered, including C-KIT, IDH1 and IDH2, NPM1, and MEK. Some lessons from the ongoing endeavor to develop FLT3 inhibitors may be applicable to the development of other targeted agents for AML.
AB - Therapy targeting specific somatic mutations has become an increasingly important part of cancer therapy over the past 20 years. In particular, tyrosine kinase inhibitors (TKIs) have become a critical component of treatment for both solid tumors and hematologic malignancies. Since mutations in the FMS-like tyrosine kinase 3 (FLT3) gene are relatively common in acute myeloid leukemia (AML), activating mutations in FLT3 represent an appealing target for drug development. Efforts are well underway to develop FLT3 inhibitors and to incorporate these agents into AML therapy. As the genetic landscape of AML has been mapped, other attractive targets for therapy have been discovered, including C-KIT, IDH1 and IDH2, NPM1, and MEK. Some lessons from the ongoing endeavor to develop FLT3 inhibitors may be applicable to the development of other targeted agents for AML.
UR - http://www.scopus.com/inward/record.url?scp=84937414408&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84937414408&partnerID=8YFLogxK
U2 - 10.1053/j.seminhematol.2015.03.004
DO - 10.1053/j.seminhematol.2015.03.004
M3 - Review article
C2 - 26111466
AN - SCOPUS:84937414408
SN - 0037-1963
VL - 52
SP - 193
EP - 199
JO - Seminars in Hematology
JF - Seminars in Hematology
IS - 3
ER -